{"id":"NCT01719003","sponsor":"Boehringer Ingelheim","briefTitle":"Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes","officialTitle":"A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-10","primaryCompletion":"2014-11","completion":"2014-12","firstPosted":"2012-11-01","resultsPosted":"2016-02-19","lastUpdate":"2016-02-19"},"enrollment":1413,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2","Hyperglycemia"],"interventions":[{"type":"DRUG","name":"Metformin 500 mg bid","otherNames":[]},{"type":"DRUG","name":"Metformin 1000 mg bid","otherNames":[]},{"type":"DRUG","name":"Empagliflozin low dose qd","otherNames":[]},{"type":"DRUG","name":"Empagliflozin high dose qd","otherNames":[]},{"type":"DRUG","name":"Empagliflozin low dose bid","otherNames":[]},{"type":"DRUG","name":"Metformin 500 mg bid","otherNames":[]},{"type":"DRUG","name":"Empagliflozin high dose bid","otherNames":[]},{"type":"DRUG","name":"Empagliflozin low dose bid","otherNames":[]},{"type":"DRUG","name":"Metformin 1000 mg bid","otherNames":[]},{"type":"DRUG","name":"Metformin 500 mg bid","otherNames":[]},{"type":"DRUG","name":"Metformin 1000 mg bid","otherNames":[]},{"type":"DRUG","name":"Empagliflozin high dose bid","otherNames":[]},{"type":"DRUG","name":"Metformin 1000 mg bid","otherNames":[]},{"type":"DRUG","name":"Empagliflozin high dose bid","otherNames":[]}],"arms":[{"label":"Empagliflozin low dose qd","type":"EXPERIMENTAL"},{"label":"Empagliflozin high dose qd","type":"EXPERIMENTAL"},{"label":"OL empa high dose + met 1000 mg bid","type":"EXPERIMENTAL"},{"label":"Empagliflozin low dose + met 500 mg bid","type":"EXPERIMENTAL"},{"label":"Empagliflozin low dose + met 1000 mg bid","type":"EXPERIMENTAL"},{"label":"Empagliflozin high dose + met 500 mg bid","type":"EXPERIMENTAL"},{"label":"Empagliflozin high dose + met 1000mg bid","type":"EXPERIMENTAL"},{"label":"Metformin 500 mg bid","type":"EXPERIMENTAL"},{"label":"Metformin 1000 mg bid","type":"EXPERIMENTAL"}],"summary":"This study will investigate the efficacy and safety of two doses (high and low) of empagliflozin in combination with metformin (500 mg and 1000 mg) administered twice daily in patients with type 2 diabetes mellitus (T2DM). Study will compare four dose combinations of empagliflozin + metformin versus each individual component after 24 weeks of treatment.","primaryOutcome":{"measure":"HbA1c (Glycosylated Haemoglobin) Change From Baseline at Week 24","timeFrame":"baseline and 24 weeks","effectByArm":[{"arm":"Empagliflozin 12.5 mg Bid+ Metformin 1000 mg Bid","deltaMin":-2.08,"sd":0.08},{"arm":"Empagliflozin 12.5 mg Bid+ Metformin 500 mg Bid","deltaMin":-1.93,"sd":0.08},{"arm":"Empagliflozin 5 mg Bid + Metformin 1000 mg Bid","deltaMin":-2.07,"sd":0.08},{"arm":"Empagliflozin 5 mg Bid + Metformin 500 mg Bid","deltaMin":-1.98,"sd":0.08},{"arm":"Empagliflozin 25 mg qd","deltaMin":-1.36,"sd":0.08},{"arm":"Empagliflozin 10 mg qd","deltaMin":-1.35,"sd":0.08},{"arm":"Metformin 1000 mg Bid","deltaMin":-1.75,"sd":0.09},{"arm":"Metformin 500 mg Bid","deltaMin":-1.18,"sd":0.08}],"pValues":[{"comp":"OG000 vs OG006","p":"0.0056"},{"comp":"OG000 vs OG004","p":"<0.0001"},{"comp":"OG001 vs OG007","p":"<0.0001"},{"comp":"OG001 vs OG004","p":"<0.0001"},{"comp":"OG002 vs OG006","p":"0.0062"},{"comp":"OG002 vs OG005","p":"<0.0001"},{"comp":"OG003 vs OG007","p":"<0.0001"},{"comp":"OG003 vs OG005","p":"<0.0001"},{"comp":"OG004 vs OG006","p":"0.6246"},{"comp":"OG005 vs OG006","p":"0.6558"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":190,"countries":["United States","Brazil","Canada","Czechia","Egypt","France","Germany","Guatemala","Lebanon","Malaysia","Mexico","Peru","Philippines","Russia","Serbia","South Korea","Spain","Taiwan","Thailand","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["27493136"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":170},"commonTop":["Urinary tract infection","Dyslipidaemia","Diarrhoea","Upper respiratory tract infection","Dizziness"]}}